Research into psychedelics presents many logistical challenges, including regulatory hurdles, storing and handling requirements, and record-keeping. In an interview with Pharmacy Times, Mark Bleackley, PhD, chief scientific officer at Incannex Healthcare Limited in Melbourne, Australia, said patient subject...
Dr. Mason Marks, a senior fellow with Project on Psychedelics Law and Regulation at Harvard,tells NPR:“I don’t think there’s any sign that progress is going to be slowed. If anything, it might intensify because the other companies might see an opportunity to really get in there...
Rabbi says psychedelics are "elephant in the room" in sacred Jewish text Women's college basketball teams to be paid for playing NCAA Tournament games Ayesha Curry on why she chose a supernatural novel for publishing debut Former Broadway designer fuels Ravens' playoff hopes from behind the...
Yes, I think we’re seeing many changes in how Americans think about psychedelics. For the first time, clinical research results are providing hard data showing that, used carefully and in the right settings, MDMA and other psychedelics can dramatically enhance the effectiveness of ther...
Idecabtagene vicleucel is a CAR T-cell therapy that recognizes and binds to B-cell maturation antigen (BCMA) on the surface of multiple myeloma cells, leading to CAR T-cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells. ...
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders. Phar...
"Although psychedelics have potential in mental health care, FDA approval of new drugs should always be based on rigorous evidence of safety and efficacy." "By rejecting the approval of MDMA, the FDA will encourage this company and other researchers of psychedelic drugs to conduct more rigorous ...
The FDA is no longer able to ignore the benefits of psilocybin and has granted "breakthrough therapy" status to this medicine to treat depression.
said in a news release. “The filing for approval of nipocalimab represents an important step forward as Johnson & Johnson continues to push the boundaries of research to develop innovative solutions to treat autoantibody-driven diseases, building on decades of expertise in neuroscience and ...
“Every day that goes by that research isn’t being done, that’s more lives being lost, primarily to suicide,” Bergman, who, with DemocratLou Correaof California, co-chairs the Psychedelics Advancing Therapies Caucus, told Erin. “A lot of those veterans are on a dark path.” Decade...